

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 230 777
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 86310075.6

(22) Date of filing: 23.12.86

(51) Int. Cl. 4: **C12N 15/00**, **C07H 21/04**,
C12N 1/20, **C12P 21/00**,
//**C07K15/00**, **A61K37/02**, (**C07H-**
21/04, **C12R1:46**, **C12N1:20**, **C12-**
R1:19)

(30) Priority: 28.12.85 JP 298014/85
21.08.86 JP 194077/86

(43) Date of publication of application:
05.08.87 Bulletin 87/32

(84) Designated Contracting States:
CH DE FR GB LI SE

(71) Applicant: SUMITOMO CHEMICAL COMPANY,
LIMITED

15 Kitahama 5-chome Higashi-ku
Osaka-shi Osaka 541(JP)

Applicant: SUMITOMO PHARMACEUTICALS
COMPANY, LIMITED

40, Doshomachi 2-chome
Higashi-ku Osaka-shi Osaka-fu(JP)

Applicant: OHGEN RESEARCH

LABORATORIES LTD.,

0-80, Yatano-cho

Komatsu-shi Ishikawa-ken(JP)

(72) Inventor: Kanaoka, Masaharu
9-5-1-136, Honmachi
Toyonaka-shi Osaka-fu(JP)

Inventor: Negoro, Takaharu
2-14-7, Mefu Takarazuka-shi

Hyogo-ken(JP)

Inventor: Kawanaka, Chigusa

6-1-56-103, Nishi-ochiai

Suma-ku Kobe-shi Hyogo-ken(JP)

Inventor: Agui, Hideo

4-5-5-203, Satsukigaoka

Ikeda-shi Osaka-fu(JP)

(74) Representative: Myerscough, Philip Boyd et al
J.A.Kemp & Co. 14, South Square Gray's Inn
London, WC1R 5EU(GB)

(54) Antitumor protein gene of streptococcus pyogenes su, plasmids containing the gene, transformant cells harboring the plasmids, and process for producing the antitumor protein.

(57) Amino acid sequence of N-terminal region of streptococcal acid glycoprotein (SAGP), and anti-tumor glycoprotein produced by Streptococcus pyogenes Su, was determined, and DNA probes

which are complementary to SAGP gene were synthesized.

Chromosomal DNA fragment of S.pyogenes Su, which hybridized with those probes was cloned into E.coli, and a restriction map of plasmid DNA harboring SAGP gene was revealed and upon it, DNA sequence or amino acid sequence of SAGP gene was determined.

ANTITUMOR PROTEIN GENE OR STREPTOCOCCUS PYOGENES SU, PLASMIDS CONTAINING THE GENE, TRANSFORMANT CELLS HARBORING THE PLASMIDS AND PROCESS FOR PRODUCING THE ANTITUMOR PROTEIN

BACKGROUND OF THE INVENTION

The present invention relates to a gene of antitumor protein produced by Streptococcus pyogenes, a vector containing the gene and microorganisms or cells transformed with the vector, and a process for producing the antitumor protein.

S.pyogenes is a Gram-positive hemolytical coccus which is known as a pathogen of erysipelas, lochiopyra, and hematospesis. It is also known that strains of S.pyogenes have antitumor activities and the sterilized cells are now clinically used as an anticancer agent.

It is reported that the substance isolated from the cells of S.pyogenes Su by monitoring *in vitro* cell growth inhibition activity has been proved to have *in vivo* antitumor activity by experiments using animals [Yoshimura, Japanese Laid-Open Patent Publication (Kokai) No. 58-222026].

Yoshimura reports that this antitumor protein is a unique glycoprotein with a molecular weight of about 50,000 (analyzed by SDS-polyacrylamide gel electrophoresis), but its amino acid sequence has not yet been revealed, nor has a gene coding for the protein been isolated.

SUMMARY OF THE INVENTION

The present invention was completed by accomplishing the cloning of a gene coding for the antitumor protein of S.pyogenes (the protein will hereinafter be referred to as SAGP) and determining its total DNA sequence and amino acid sequence, producing vectors containing SAGP gene sequence and being capable of expressing SAGP in host cells, cultivating host cells transformed with the vectors and confirming the production of SAGP by the host cell. The invention makes it possible to produce SAGP safely on a large scale without cultivating pathogenic microorganisms.

The present invention provides an SAGP gene, DNA containing the gene, a recombinant plasmid containing SAGP gene and microorganisms or cells containing the plasmid, and a process for producing SAGP by cultivating the microorganisms or cells transformed with the plasmids. SAGP so obtained can be used as an anti-tumor agent.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a restriction map of plasmid pSP1. Figure 2 is the base sequence of an inserted DNA fragment of pSP1 and the amino acid sequence deduced from SAGP gene base sequence. The base number 40 -1219 region is the region coding for SAGP. ATG, an initiation codon coding for Met exists upstream of the amino acid sequence coding for Thr of N terminal region of SAGP. The number of amino acids of SAGP is deduced to be 410. Figure 3 shows a brief chart for illustrating construction of expression vectors having inserted therein a purified DNA fragment of SAGP gene prepared by digesting pSP1, plasmid containing SAGP gene, with EcoRI.

DETAILED DESCRIPTION OF THE INVENTION

SAGP gene isolated from S.pyogenes by the present invention has the DNA sequence shown in Fig. 2 and, by using the information on the DNA sequence of Fig. 2, SAGP gene can now easily be isolated from S.pyogenes by procedures conventionally used in the field of the present invention.

SAGP gene isolated from S.pyogenes Su is, so to speak, natural DNA (base) sequence.

Today, the DNA synthesis technology makes it possible to synthesize DNA coding for a given protein, once the amino acid sequence of the protein is elucidated.

As is well known, most amino acids have more than one DNA base sequence or codon coding for them. Therefore, more than one DNA coding for a particular protein can be synthesized.

Accordingly, in synthesizing SAGP gene coding for the SAGP amino acid sequence in this invention, the DNA sequence is not limited to the natural SAGP gene DNA sequence, but contains all other DNA sequences coding for the SAGP amino acid sequence elucidated by the present inventors.

The present gene recombination technique can induce artificial mutation on a specific region of DNA sequence without making any substantial change or with an improvement of the basic characteristic of what is encoded by the DNA sequence.

As to SAGP gene of this invention, it is possible to prepare SAGP genes having the same or better characteristic as or than that of the natural SAGP gene by artificial insertion, deletion or substitution.

This invention encompasses such variant SAGP genes in addition to the natural gene.

Expression vectors which enable the production of SAGP in host cells can be prepared by inserting SAGP gene into suitable expression vectors using procedures commonly used in the field of the present invention.

Expression vectors used in this invention contain a SAGP gene sequence and a DNA sequence which controls the expression of SAGP gene in host cells upstream of the SAGP gene sequence, and are capable of replicating in the host cells.

More specifically, the expression vector essentially has a promotor sequence upstream of the SAGP gene and the origin of replication, i.e. DNA sequence controlling replication of the vector in a host cell.

As a promotor, known promotors such as lac promotor, trp promotor or lpp promotor can be used alone or in combination when E.coli is used as a host cell. These examples are not limitative, however.

In addition, the vector desirably contains a drug resistant gene to make it easy to select a host cell containing the vector.

For example, an ampicilin resistant gene and a tetracyclin resistant gene can be used as the drug resistant gene when E.coli is used as a host cell.

In the field of genetic engineering today, E.coli is most genetically analyzed and regarded as safest as host cells, and hence E.coli is most frequently used.

For the replication of SAGP gene and production of SAGP, it is desirable to use E.coli, as host microorganism, because E.coli can multiply rapidly and it is easy to control expression of SAGP gene in E.coli.

But it is possible to use some other kinds of bacteria, yeast, and so on, as a host cell together with adequate expression vectors which can replicate in microorganisms to be used.

Transformed E.coli is cultivated in a suitable medium and production of SAGP is confirmed by the Ouchterlony method or the Western blotting method.

SAGP may be isolated from the medium by methods conventionally used in the field of the invention.

The individual steps mentioned above will be described in detail.

1. Isolation of DNA fragment containing SAGP gene sequence:

SAGP gene may be isolated from S.pyogenes by a conventional method when the information on the DNA or amino acid sequences of SAGP given by the invention is used. More specifically, it can be isolated for example, through the following procedures:

1) Synthesis of probes, short length DNA that is complementary to SAGP gene:

Short length DNA's each of which has the base sequence complementary to the DNA sequence of SAGP gene described in Figure 2 are synthesized.

It is possible to obtain adequate probes by determining the amino acid sequence of purified SAGP gene, deducing a DNA sequence from the amino acid sequence and synthesizing short length DNAs which have the deduced DNA sequence.

2) Extraction of S.pyogenes chromosomal DNA and digestion with restriction enzyme and fractionation.

After cultivation of S.pyogenes, the cells are lysed with an enzyme and/or a detergent, then the chromosomal DNA is extracted and purified from the lysed cells by a known method [J. Marom J. Mol. Biol., 3, 280 (1961)]. The extracted chromosomal DNA is digested with a restriction enzyme.

The digested chromosomal DNA is subjected to agarose gel electrophoresis, and then fractionated according to the length of DNA fragments.

The DNA fragments are transferred and immobilized on a nitrocellulose filter by the Southern's method [E. M. Southern, J. Mol. Biol., 98, 503 - (1975)]. By Southern hybridization with the RI-labeled DNA probes, the length of DNA fragments containing SAGP gene was determined.

3) Insertion of the DNA into a vector and transformation of host E.coli with the resulting recombinant vector:

DNA fragments of such a size that contains SAGP gene are isolated from the digested chromosomal DNA fragments fractionated by agarose gel electrophoresis and then ligated with vector DNA previously digested with the same re-

striction enzyme by DNA ligase. The ligation mixture is introduced into E.coli to give transformed cells.

4) Selection of transformant carrying SAGP gene:

The transformants obtained in 3) are grown on a nitrocellulose filter and lysed, and then the DNA fragment from lysed cells is immobilized on the filter. By hybridization of the immobilized DNA fragment described above with RI-labeled probe, the transformed cells containing SAGP gene is identified.

5) Isolation of Plasmid DNA:

The transformants determined to contain SAGP gene as in 4) are cultivated, and then plasmid DNA is isolated from them by a known method [T. Maniatis, E. F. Fritsch, J. Sambrook, Molecular Cloning, p.86, Cold Spring Harbor Laboratory - (1982)].

6) Preparation of a restriction enzyme map of plasmid DNA:

The plasmid DNA isolated in 5) is digested with restriction enzymes, the length of each fragment is determined by electrophoresis and a restriction enzyme map of the plasmid DNA is prepared.

7) Determination of DNA sequence of SAGP gene:

Based upon the restriction enzyme map prepared in 6), SAGP gene DNA is digested into shorter length fragments with restriction enzymes and each fragment is cloned. Then, its base sequence is determined by the Sanger method [G. F. Hong, Biosci.Report, 2, 907 (1982)].

In addition, the base sequences of the DNA fragments are also determined by the Maxim-Gilbert method [A. Maxam and W. Gilbert, Method in Enzymology, 65,499 (1980)].

8) Isolation of DNA fragment containing SAGP gene sequence from the plasmid vector carrying the gene:

Plasmid vector containing SAGP gene sequence is digested with a restriction enzyme.

The DNA fragments of digested vector are fractionated by polyacrylamide gel electrophoresis, and a 2100 base pair DNA fragment containing SAGP gene is extracted and purified from the gel.

2. Construction of expression vector:

SAGP gene is inserted into an expression vector.

For example, commercially available plasmid pKK 233-3 or pIN III is digested at a site downstream of the promoter with restriction enzyme EcoRI, and mixed with DNA fragment containing SAGP gene described above and ligated with T4-DNA ligase.

3. Transformation of host E.coli

The expression vector ligated with DNA containing SAGP gene is introduced into E.coli by a conventional transformation method.

Plasmid DNA is prepared from the transformants obtained above and the transformant containing expression vector is selected by analyzing its restriction enzyme digestion pattern.

4. Cultivation of transformed E.coli and induction of expression of SAGP gene:

E.coli transformed by the expression vector described in 3 is inoculated and incubated in a liquid medium at 37°C.

Growth of bacteria is observed by measuring the optical density of the culture medium and at the proper step of growth, expression of SAGP gene is induced by adding Isopropyl- β -D-thiogalactoside (IPTG), for example. After that, the transformants are further cultivated.

5. Harvest of cells and isolation of SAGP

The liquid culture described in 4 is centrifuged to harvest the cells.

The harvested E.coli cells are lysed with lysozyme, or a detergent, or by sonification, for example and SAGP can be isolated from the mixture by a conventional method.

SAGP is purified from all the lysate through analogous methods adopted for purification of SAGP from cultured cells of S.pyogenes Su; they are ammonium sulfate precipitation, Octyl-Sepharose CL-4B column chromatography, DE-52 ion-exchange chromatography and TSK gel G3000SW gel filtration.

Production of SAGP is confirmed by analyzing the lysed mixture by the Ouchterlony method or the western blotting method.

Example 1

1. Isolation of SAGP gene

1) Determination of amino acid sequence of N-terminus of SAGP

SAGP was purified by a known method - (Yoshimura, Japanese Patent Publication (Kokai) No. 58-222026) from *S.pvogenes* Su. (ATCC 21060) and using purified SAGP 100 µg, the amino acid sequence of N terminus was analyzed by gas-phase protein sequencer (Applied Biosystems Model 470A). As a result, the amino acid sequence of N-terminus of SAGP was determined as follows: Pro (or Thr)-Ala-Glu-Thr-Pro-Ile-Unk-Val -Tyr-Unk-Unk-Ile-Gly-Lys-Leu-Lys-Lys-Val-Leu -Leu-His-Unk-Pro-Gly-Lys
In the formula, Unk means "unknown".

2) Synthesis of Probe

Based upon the amino acid sequence determined above, 2 kinds of mixed probe P-37 and P-38, short length DNA fragments coding for a part of the amino acid sequence, were synthesized.

The P-37 corresponds to the amino acid sequence Pro-Ala-Glu-Thr-Pro-Ile, and contains DNAs of the following sequences:
CC(T,A)GC(T,A)CAAAC(A,T)CC(T,A)AT(A,T)T.

The P-38 corresponds to the amino acid sequence Ile-Gly-Lys-Leu-Lys-Lys-Val, and contains DNAs of the following sequences:
AT(T,A)GG(T,C)AAATT(A,G)AAAAAAGT.

The P-37 is a mixture of 32 kinds of DNA sequences and P-38 is a mixture of 8 kinds of DNA sequences, as mentioned above.

They were synthesized by automatic DNA synthesizer (Applied Biosystems Model 380A) to yield 146 µg of the P-37 and 244 µg of the P-38.

These probe DNA were ³²P-labeled as follows just before the hybridization.

Synthetic probe 5pM was incubated with T4-polynucleotide kinase and (γ³²P)-ATP30 Ci at 37°C for 30 minutes.

After the reaction product was adsorbed on a small amount of DE-52, and nonreacted (γ³²P)-ATP was washed away with 0.1M-NaCl solution, ³²P-labeled probe was extracted from the DE-52 with 1M-NaCl solution.

3) Extraction and digestion with restriction enzyme of chromosomal DNA of *S.pvogenes* Su

S.pvogenes Su (ATCC 21060) was cultivated in L culture medium 300 ml at 37°C for 15 hours, and then cells were harvested by centrifugation.

The cells were suspended in 0.15M NaCl - 0.1M EDTA solution, and lysed with lysozyme, pronase and sodium dodecylsulfate (SDS).

Chromosomal DNA was extracted from the lysate, and purified by a known method [J. Marmur, *J. Mol. Biol.*, **3**, 208 (1961)]

The chromosomal DNA 5 µg was incubated with restriction enzyme EcoRI at 37°C for 1 hour and the digested DNA was subjected to 1% agarose gel electrophoresis.

This agarose gel was soaked in 0.2M NaOH - 0.5M NaCl solution, so that DNA was denatured, and washed with tria-acetate-EDTA buffer for 10 minutes 3 times.

Then DNA on agarose gel was electrophoretically transferred to Zeta-Probe filter. - (Electrophoresis was done at 30V overnight). The filter was headed at 80°C for 3 hours after air-drying at room temperature for 30 minutes.

Two Zeta-Probe filters on which DNA was immobilized by the above method were prehybridized with 4 x SSC [Blin et al., *Nucleic Acid Research*, **3**, 2303 (1976)], 50x Denhart • [Wahl et al., *Proc.Natl.Acad.Scie.*, **76**, 3683 (1979)], 1% SDS and sonicated salmon sperm DNA solution 10 µg/ml at 60°C for 3 hours.

Then, the filters described above were hybridized with the same solution containing 100,000 cpm labeled P-37 probe or P-38 probe at 40°C for 18 hours.

The filters were air-dried after 4 times washing with 4 x SSC at 40°C 15-30 minutes, and then exposed to X-ray films for 48 hours.

As a result, both hybridization with P-37 probe and with P-38 probe revealed that there exists a band hybridized on the position of about 2 kbp DNA fragment.

4) Insertion of chromosomal DNA fragment into vector and transformation of *E.coli*

Chromosomal DNA 50 µg was digested by incubating it with restriction enzyme EcoRI at 37°C for 1 hour and then applied to 1% agarose gel electrophoresis. The regions of the gel containing about 1.8-2.2 kbp fragment was cut out, from which DNA fragment was extracted.

The chromosomal DNA mentioned above was mixed with plasmid vector pUC19 (Takara Shuzo) digested with EcoRI and reacted with T4-DNA ligase at 17°C overnight. *E.coli* JM103 was trans-

formed with the reaction mixture [M. Mandel and A. Higa, *J. Mol. Biol.*, 53, 159 (1970)], inoculated on L-agar medium containing 5-bromo-4-chloro-3-indolyl- β -D-galactoside (X gel), isopropyl- β -D-thiogalactoside (IPTG) and ampicillin and then cultivated at 37°C overnight, from which sixty-four white colonies were picked up.

5) Selection of transformant carrying SAGP gene

Each of the sixty-four transformed *E. coli* JM103 obtained above was inoculated in nitrocellulose filter on L-agar medium and cultivated at 37°C for 6 hours.

The filter was transferred to L-agar medium containing ampicillin, chloramphenicol and cultivated at 37°C overnight.

After cultivation, the filter was treated with 10% SDS for 5 minutes, with NaOH-1.5M NaCl for 3 minutes, and with 1M Tris-HCl buffer for 5 minutes so that bacteria on the filter were lysed. The DNA of them was immobilized on the filter by heating it at 80°C for 3 hours.

Hybridization with the labeled P-38 probe described above and exposure to X-ray film revealed that two colonies among sixty-four colonies were hybridized with the probe.

6) Isolation of Plasmid DNA

Two colonies revealed to have SAGP gene were cultivated and plasmid DNA was obtained by a known method [T. Maniatis, E. F. Fritsch, J. Sambrook, *Molecular Cloning*, p.86, Cold Spring Harbor Laboratory (1982)].

The plasmid DNA obtained from the two positive clones were analyzed with several restriction enzymes. Consequently they represented the same restriction pattern, and were found to be identical to each other. They were named pSP1.

7) Preparation of pSP1 restriction map

Plasmid pSP1 obtained above was digested with restriction enzymes, EcoRI, HindIII, PstI, ClaI, NcoI, AclI, HpaI, HincII, AhaII, BstI, HaeII, MluI independently or in combination, and the digested DNA fragments were applied to agarose gel or acrylamide gel electrophoresis to determine the length of fragments to prepare the restriction map of pSP1.

Consequently, it was revealed that pSP1 was a plasmid wherein about 2 kbp foreign DNA fragment was inserted into the EcoRI site of pUC19.

8) Determination of SAGP gene DNA sequence

Based upon the restriction map described above, inserted DNA fragments of pSP1 were further digested with restriction enzymes and cloned into pUC19, and using them, DNA sequencing was carried out by the dideoxy method [G. F. Hong, *Biosci. Report*, 12,907 (1982)]. Sequencing kit manufactured by Takara Shuzo, and M-4 or RV as a primer (Takara Shuzo) was used. The DNA sequence of each fragment was determined to elucidate the entire 2157bp sequence containing SAGP gene.

9) Isolation of DNA fragment containing SAGP gene from the plasmid vector

Plasmid pSP1 containing SAGP gene sequence obtained above 12.5 μ g was digested with restriction enzyme EcoRI (Takara Shuzo) 50 units at 37°C for 2 hours.

This digested mixture was fractionated with 5% polyacrylamide gel electrophoresis and the region of the gel containing DNA fragment of 21000 bp was cut out.

DNA was extracted from the cut out gel with Tris-EDTA buffer.

The extract was purified by washing with phenol and precipitation with ethanol to give 21000 bp DNA fragment containing SAGP gene.

2. Construction of expression vector

Two micrograms of pKK 223-2 (Pharmacia-PL), a plasmid DNA for construction of expression vector containing trp and lac promoters (tac promoter) and ampicillin resistant gene was digested with restriction enzyme EcoRI 6 unit at 37°C overnight which was then reacted with alkaline phosphatase at 37°C for 30 minutes to remove 5'terminal phosphate residue.

DNA was recovered from the mixture by washing with phenol and precipitation with ethanol.

pIN III A1 plasmid DNA containing lpp and lac promoter and ampicillin resistant gene [Inouye *EMBO Journal*, 1, 771 (1982)] was digested with EcoRI and 5'terminal phosphate was removed with alkaline phosphatase by the same method as above. The DNA fragment containing SAGP prepared in 1, 9 above was mixed with the vector DNAs described above, and the mixtures were

reacted with T4-DNA ligase (Takara Shuzo) at 4°C overnight to ligate them and produce expression vectors pIN III SP and ptac SP, as illustrated in Fig. 3.

3. Transformation of host *E.coli*

E.coli JM 103 was transformed by a known method [T. Maniatis, Molecular Cloning, p.250, Cold Spring Harbor Laboratory (1982)] with the expression vector described above.

20 -30 clones for each transformant obtained above were cultured and their plasmid DNA was isolated by a known method (T. Maniatis, Molecular Cloning, p.86, Cold Spring Harbor Laboratory) and digested with various kinds of restriction enzymes. The digestion patterns were analyzed by agarose gel electrophoresis, so that clones of transformant *E.coli* JM103 (pIN III SP) (ATCC 67271), carrying pIN III SP and *E.coli* JM103 (ptac SP) (ATCC 67272) carrying ptac SP were selected.

4. Cultivation of transformed *E.coli* and induction of the expression of SAGP gene

Each of the transformed *E.coli* cells carrying expression vector described above was inoculated in LB medium (T. Maniatis, Molecular Cloning, p.440, Cold Spring Harbor Laboratory) 100 ml, and incubated at 37°C.

Growth of the culture was observed by measuring its optical density at 550 nm. When OD₅₅₀ reached 0.2, IPTG(Isopropyl-β-D-thiogalactoside) 0.1 mM (final concentration) was added to the medium and expression of SAGP was induced. The cultivation was continued.

After the induction, a small amount of the medium was periodically taken out to examine production of SAGP.

At the same time, *E.coli* harboring pKK 233-3 or pIN III AI was cultivated and IPTG was added. The medium was examined in the same way as controls.

5. Confirmation of the production of SAGP

Cells in the sampled culture medium described above were harvested by centrifugation and the harvested cells were lysed by reacting with lysozyme 2 mg/ml at 0°C for 30 minutes, and adding 1% Triton-X100 (Wako Pure Chemicals Co., Ltd.).

When the lysate was reacted with anti-SAGP rabbit antiserum by Ouchterlony method [O. Ouchterlony, *Prog. Allergy*, 6, 30 (1962)] at 37°C overnight, an obvious sedimentation line was represented by the antigen-antibody reaction if it was the lysed mixture of the cells containing pIN III SP or ptacSP, or SAGP isolated from *S.pyogenes*. In the case of mixtures containing pIN III AI or pKK 233-3, as control experiment, no sedimentation line was observed.

The lysed mixture was fractionated by 12.5% SDS-polyacrylamide gel electrophoresis, and the protein was transferred to a nitrocellulose filter by Western blotting method [W.N. Burnette, *Anal. Biochem.*, 112, 195 (1981)] and immobilized.

The filter was soaked in a buffer solution containing anti-SAGP rabbit antiserum at 37°C for 30 minutes, and also at 40°C overnight. Unreacted anti-SAGP antibody was washed away with the buffer, and the filter was soaked in a buffer solution containing alkaline phosphatase-anti-rabbit IgC antibody at 37°C for 2 hours, whereby anti-SAGP antibody on the filter was reacted with it.

When the filter was washed and soaked in the buffer containing BCIP (5-Bromo-4-chloro-3-indolyl-phosphate) for coloration, a band formed by the antigen-antibody reaction was observed in the same molecular weight (Ca. 47,000 daltons) region as SAGP isolated from *S.pyogenes* in the cases of the transformant *E.coli* containing ptac SP or pIN III SP.

Another *E.coli* containing pKK 233-3 or pIN III AI, used as control experiment, did not represent such band.

Accordingly, production of SAGP by *E.coli* containing expression vectors described above was confirmed.

Example 2

Purification and N-terminal amino acid sequence of SAGP produced in *E.coli* JM103-(ptacSP)

In order to confirm the amino acid sequence of the expressed protein in *E.coli*, the expressed protein was purified and the N-terminal amino acid sequence was determined as follows.

1) Assay Method

At each step of the purification process, the fractions containing SAGP were determined by an enzyme linked immunosorbent assay method.

The samples and the standard SAGP were diluted by phosphate buffered saline (PBS), containing NaCl 8g, KCl 0.2g, NaHPO₄·12H₂O 2.9g and KH₂PO₄ 0.2g per liter, and 100 µl of diluted solutions was put into each well of a 96-well flexible assay plate (Falcon® 3912) which had been washed by distilled water. After the plate was maintained at 37°C for 2 hours, solutions in the wells were removed and 200 µl blocking solution (2% bovine serum albumin and 0.05% Tween® 20 in PBS) was poured into the each well and placed at 37°C for 2 hours. The blocking solution was removed and then the assay plate was washed with PBST (0.05% Tween® 20 in PBS). Then 100 µl of the anti-SAGP rabbit anti-serum which was diluted to 10000-fold by PBST containing 1% BSA was put into each well and the plate was maintained at 37°C for 2 hours. After the anti-serum solution was removed, the assay plate was washed with PBST. Then 100 µl of alkaline phosphatase linked anti-rabbit-IgG anti-serum (Miles Scientific) which was diluted to 3000-fold with PBS was put into each well and the assay plate was maintained at 37°C for 2 hours. After the enzyme linked anti-serum solution was removed, the assay plate was washed with PBST. Then 100 µl of a substrate solution which contained 0.3% disodium p-nitrophenyl-phosphate in 10% diethanolamine buffer (pH 9.1) was put into each well and the assay plate was maintained at 37°C for 15 minutes. To stop the enzyme reaction, 20 µl each of 1N NaOH was added. SAGP contained in sample solutions was identified and quantified by measuring the absorbance of 450 nm light of the reaction mixtures.

2) Cultivation of E.coli JM103(ptacSP)

The cells of E.coli JM103(ptacSP) maintained on a LB-agar medium containing 50 µg/ml ampicillin were inoculated and cultivated in 5 ml LB medium containing 100 µg/ml ampicillin in test tubes for 14 hours at 37°C. Five milli-liters of the pre-culture broth was inoculated in 12 flasks of 2-liter volume each containing 500 ml LB-ampicillin (100 µg/ml medium). Then the E.coli cells were cultivated at 37°C for 24 hours in a rotary shaker - (New Brunswick Scientific Inc. model G-25) at 280 rpm.

After the cultivation, the cells were harvested using a TOMY RS-20BH centrifuge equipped with a BH-9 rotor (10000 rpm, 10 min).

The separated cells were resuspended in 200 ml PBS and lysed by using a BRANSON SONIFIER. The ruptured cell suspension was centrifuged (TOMY BH-9 rotor 10000 rpm, 10 min) and the pellet was removed.

3) Ammonium sulfate precipitations

The supernatant of the cell lysate was brought to 20% saturation with respect to ammonium sulfate and was stirred for 2 hours at 4°C followed by standing for 2 hours. The solution was centrifuged - (Sorvall GSA rotor 10000 rpm, 15 min) and the pellet was removed. Then the supernatant was brought to 70% saturation with respect to ammonium sulfate and stirred for 2 hours at 4°C followed by standing overnight. The solution was centrifuged (Sorvall GSA rotor 10000 rpm, 15 min) and the pellet was recovered.

4) Octyl-Sepharose CL-4B column chromatography

The ammonium sulfate precipitate described above was dissolved in 6 ml of 10 mM potassium phosphate (pH 7.0) and applied to an Octyl-Sepharose CL-4B (Pharmacia) column (25ø x 600 mm), which had previously been equilibrated with 10 mM potassium phosphate (pH 7.0). The chromatography was performed by 800 ml of 10 mM potassium phosphate (pH 7.0) with ethylene glycol gradient (from 0 to 50%); flow rate 1 ml/min, 8 ml/fraction. The fractions from No. 22 to No. 38 were collected and dialysed against distilled water then lyophilized.

5) DE-52 ion-exchange chromatography

The SAGP fraction mentioned above was then dissolved in 5 ml of 10 mM potassium phosphate - (pH 7.0) and applied to an DE-52 (Whatman) column (15ø x 600 mm), which had been previously equilibrated with 10 mM potassium phosphate (pH 7.0). Chromatography was performed by 800 ml of potassium phosphate (pH 7.0) with the salt concentration gradient (from 10 to 500 mM); flow rate 0.7 ml/min, 8 ml/fraction. The fractions from No. 48 to No. 58 were collected, dialysed against distilled water, and then lyophilized.

6) DEAE-Sephadex ion-exchange chromatography

The SAGP fraction mentioned above dissolved in 5 ml of 10 mM sodium phosphate (pH 7.0 and applied to an DEAE-Sephadex A-25 (Pharmacia) column (15ø x 500 mm), which had been previously equilibrated with 10 mM sodium phosphate (pH 7.0). Chromatography was performed by 300 ml of 10 mM sodium phosphate with NaCl gradient (from 0 to 500 mM); flow rate 0.35 ml/min, 3 ml/fraction. The fractions from No. 56 to No. 66 were collected, dialysed against distilled water, and then lyophilized.

7) TSK G-3000SW gel filtration

The SAGP fraction mentioned above was dissolved in 2 ml of PBS and 200 µl of the solution was applied to a TSK G-3000SW (Toyo Soda) gel filtration HPLC column (7.5 x 600 mm). Chromatography was performed by using PBS as an eluant; flow rate 0.3 ml/min. The eluate whose retention time was from 53.5 min to 56.8 min was recovered. This gel filtration was repeated once.

The recovered solution was desalted by using a Sephadex PD-10 (Pharmacia) column, and then lyophilized.

8) SDS-polyacrylamide gel electrophoresis

The recovered eluates mentioned above was then applied to a 12.5% SDS-polyacrylamide gel electrophoresis and a gel piece which contained a protein whose mobility corresponded to a molecular weight 4.7 kg was cut out.

The protein in the gel piece was electrophoretically eluted by a known method [M. W. Hunkapiller *et al*, Methods in Enzymology, 91, 227 (1983)].

9) N-terminal amino acid sequencing

The protein recovered from the SDS-polyacrylamide gel mentioned above was applied to a Protein Sequencer model 470A (Applied Biosystems).

The deduced N-terminal amino acid sequence was as follows.

Thr-Ala-Gln-Unk-Pro-Ile-Unk-Val-Tyr

The amino acid sequence was in agreement with the N-terminal portion of SAGP produced by S.pyogenes Su without the 4th and 7th amino acids; th y are threonine and histidine in the native SAGP and both of them are hardly detectable by the adopted sequencing method. Since methionine

was also detected as the N-terminus together with threonine by the amino acid sequencing, it was not denied that the SAGP produced by E.coli contained a protein whose N-terminal methionine was not processed.

Thus it was confirmed that the cloned gene was correctly translated to the amino acid sequence of SAGP.

Claims

1. DNA coding for an antitumor protein produced by Streptococcus pyogenes.

2. DNA according to Claim 1, which is characterized by coding for the antitumor protein specified by the amino acid sequence shown in Figure 2.

3. DNA according to Claim 2, which is characterized by having the base sequence shown in Figure 2 as coding for the antitumor protein.

4. DNA containing a DNA sequence as claimed in Claim 1, 2 or 3.

5. DNA according to Claim 4, which is self-replicating.

6. DNA according to Claim 5, which is specified as plasmid pSP1.

7. Expression vector which harbors DNA as claimed in any one of the preceding claims and which expresses the antitumor protein produced by S.pyogenes in host cells.

8. Expression vector according to Claim 7, which is specified as ptac SP.

9. Expression vector according to Claim 7, which is specified as pIN III SP.

10. Expression vector according to Claim 7, 8 or 9, which is characterized in that the host cell is E.coli.

11. A microorganism containing DNA coding for an antitumor protein produced by Streptococcus pyogenes.

12. Microorganism according to Claim 11, which belongs to E. coli.

13. Microorganism according to Claim 12, which is E.coli JM 103 (pSP1) (ATCC 67270).

14. A method for producing an antitumor protein which comprises cultivating transformant cells transformed with an expression vector as claimed in Claim 7, 8, 9 or 10.

15. A method according to Claim 14, which comprises cultivating E.coli JM 103 (pIN III SP) - (ATCC 67271) or E.coli JM 103 (ptac SP) (ATCC 67272).

Fig. 1

RESTRICTION ENZYME MAP OF pSP1




Fig. 2-2

730 740 750 760 770 780
AAAGATGTGCTTGCGGTTGGTATTTCTCAACGTACAGATGCTGCTTCTATTGAAAAATTG
LysAspValLeuAlaValGlyIleSerGlnArgThrAspAlaAlaSerIleGluLysLeu

790 800 810 820 830 840
TTGGTTAACATCTTTAAACAAAACCTTGGCTTCAAGAAAGTATTGGCCTTTGAATTTGCA
LeuValAsnIlePheLysGlnAsnLeuGlyPheLysLysValLeuAlaPheGluPheAla

850 860 870 880 890 900
AATAACCGTAAATTTATGCACTTAGACACTGTCTTTACCATGGTTGACTATGACAAATTT
AsnAsnArgLysPheMetHisLeuAspThrValPheThrMetValAspTyrAspLysPhe

910 920 930 940 950 960
ACCATTACCCAGAAATTGAAGGAGACCTTCGTGTTTACTCTGTCACTTACGACAATGAA
ThrIleHisProGluIleGluGlyAspLeuArgValTyrSerValThrTyrAspAsnGlu

970 980 990 1000 1010 1020
GAACTTCATATCGTTGAAGAAAAAGGTGATTTAGCAGAACTTCTTGCTGCTAACCTTGGT
GluLeuHisIleValGluGluLysGlyAspLeuAlaGluLeuLeuAlaAlaAsnLeuGly

1030 1040 1050 1060 1070 1080
GTTGAAAAAGTTGACCTTATCCGTTGTGGTGGTGACAACTTAGTAGCAGCAGGTCGTGAA
ValGluLysValAspLeuIleArgCysGlyGlyAspAsnLeuValAlaAlaGlyArgGlu

1090 1100 1110 1120 1130 1140
CAATGGAACGATGGTTCTAACACCCTTACTATCGCACCAGGTGTGGTTGTGGTTTATAAC
GlnTrpAsnAspGlySerAsnThrLeuThrIleAlaProGlyValValValValTyrAsn

1150 1160 1170 1180 1190 1200
CGTAACACCATTACCAATGCTATTCTTGAATCTAAAGGCTTGAAATTGATCAAGATTAC
ArgAsnThrIleThrAsnAlaIleLeuGluSerLysGlyLeuLysLeuIleLysIleHis

1210 1220 1230 1240 1250 1260
GGAAGTGAATTGGTTCGCGGTCGTGGTGGACCTCGTTGTATGTCAATGCCATTTGAACGT
GlySerGluLeuValArgGlyArgGlyGlyProArgCysMetSerMetProPheGluArg

1270 1280 1290 1300 1310 1320
GAAGATATTTAATAAGCTATGGTAAAGGTGGTTATAGGTCAGAAGCCTTTTTAAAGGGCA
GluAspIle

1330 1340 1350 1360 1370 1380
GCTAGTGTTTATCTTCGCTTCTGTGTCTTTGTCCCTCAATGAAATTTGTTCATGACAGAT

1390 1400 1410 1420 1430 1440
AAATTTGATGCCAATGACGAAACAAGAACGGTTTATGCAGTCGTTTATGACAATGACCAG

1450 1460 1470 1480 1490 1500
CCCGTTTCAACAGGACAATTTTAGCTGAAACGAAAATAGAAGCACGATTGACACGCATT

Fig. 2-3

1510 1520 1530 1540 1550 1560
GTAACCTTAGCAGATTATTGTGGTTGCGGTTATGGTGCCAAAGTCACTGAAGCGCTAGAA

1570 1580 1590 1600 1610 1620
ACTTATACCAGACGAGAAGGCTTTTACCAACTAACCATTACAGTGAAGTGAAGCAGACAA

1630 1640 1650 1660 1670 1680
ACCTTTTATGAAAACCTAGGTTATCAGACCTATGGTTCCAAGTATTTAGAAGATGGTGAG

1690 1700 1710 1720 1730 1740
TATTGTCAATCCCTTGTTAAAACCATCTTAAATGGGAGAAGAATATGGACATAGCAATG

1750 1760 1770 1780 1790 1800
CTAATTGCGATTGTTGGTGGTCTATTAGGCTGCTATCTCTATCTCACAAAAATAATGAA

1810 1820 1830 1840 1850 1860
CCCAAAGATTAAGTTAATACTCGAAGGAGACAATAGATGACACAAGTATTTCAAGGACGT

1870 1880 1890 1900 1910 1920
AGCTTCCTAGCAGAAAAAGATTTTACACGCGCTGAATTAGAATACCTTATTGATTTTTCA


1930 1940 1950 1960 1970 1980
GCTCATTTGAAAGATTTGAAAAAACGTGGTGTGCCTCATCACTACTTAGAAGGTAAAAAC

1990 2000 2010 2020 2030 2040
ATTGCCCTCTTGTTTGAAAAAACATCAACTCGTACGCGTGCAGCTTTTACAACAGCAGCC

2050 2060 2070 2080 2090 2100
ATTGACCTAGGTGCTCACCCAGAATACCTCGGTGCCAATGACATCCAACCTTGGTAAAAAA

2110 2120 2130 2140 2150
GAATCAACAGAAGACACTGCTAAAGTATTGGGTCGTATGTTTGATGGGATTGAATTC

Fig. 3





DOCUMENTS CONSIDERED TO BE RELEVANT			EP 86310075.6
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	WO - A1 - 85/00 832 (THE ROCKEFELLER UNIVERSITY) * Claims 1,11,12,14 *	1,7, 10-12, 14	C 12 N 15/00 C 07 H 21/04 C 12 N 1/20 C 12 P 21/00
A	EP - A2 - 0 135 820 (CHUGAI SEIYAKU KABUSHIKI KAISHA) * Claim 2 *	1	// C 07 K 15/00 A 61 K 37/02 (C 07 H 21/04
A	PATENT ABSTRACTS OF JAPAN, unexamined applications, field C, vol. 9, no. 233, September 19, 1985 THE PATENT OFFICE JAPANESE GOVERNMENT page 100 C 304 * Kokai-NO. 60-92 218 (JIYUZOUDAKA)	1	C 12 R 1:46 C 12 N 1/20 C 12 R 1:19
A	US - A - 4 306 024 (INCUE et al.) * Abstract *	1	TECHNICAL FIELDS SEARCHED (Int. Cl.4) C 12 N C 07 H C 12 P C 07 K A 61 K
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 02-04-1987	Examiner WOLF
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	



DOCUMENTS CONSIDERED TO BE RELEVANT			EP 86310075.6
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
X	WO - A1 - 85/00 832 (THE ROCKEFELLER UNIVERSITY) * Claims 1,11,12,14 *	1,7, 10-12, 14	C 12 N 15/00 C 07 H 21/04 C 12 N 1/20 C 12 P 21/00
A	EP - A2 - 0 135 820 (CHUGAI SEIYAKU KABUSHIKI KAISHA) * Claim 2 *	1	// C 07 K 15/00 A 61 K 37/02 (C 07 H 21/04 C 12 R 1:46 C 12 N 1/20 C 12 R 1:19)
A	PATENT ABSTRACTS OF JAPAN, unexamined applications, field C, vol. 9, no. 233, September 19, 1985 THE PATENT OFFICE JAPANESE GOVERNMENT page 100 C 304 * Kokai-NO. 60-92 218 (JIYUUZOU UDAKA)	1	
A	US - A - 4 306 024 (INCUE et al.) * Abstract *	1	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			C 12 N C 07 H C 12 P C 07 K A 61 K
Place of search VIENNA		Date of completion of the search 02-04-1987	Examiner WOLF
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>			

